Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLynch, Craig-
dc.contributor.authorZimet, Allan-
dc.description.abstractPeritoneal carcinomatosis has a relentlessly aggressive clinical course. Pressurized Intraperitoneal Aerosol Chemotherapy entails accessing the abdominal cavity using standard laparoscopic techniques and delivering aerosolized chemotherapeutic agents via a high pressure micro injection pump. This novel therapeutic approach can repeatedly deliver a localised therapy with enhanced tolerability and minimal morbidity to improve local disease control. Early results suggest PIPAC is feasible, safe, and well tolerated. Patients having repeated PIPAC procedures had increased survival. Limitations include the small sample size and heterogeneity of the patient group.en_US
dc.subjectPeritoneal Canceren_US
dc.subjectPressurized Intraperitoneal Aerosol Chemotherapyen_US
dc.subjectHigh Pressure Micro Injection Pumpen_US
dc.subjectLocalised Therapyen_US
dc.subjectEnhanced Tolerabilityen_US
dc.titlePIPAC for peritoneal cancer: The Epworth experience.en_US
dc.typeConference Posteren_US
dc.description.affiliatesANU College of Health & Medicine, The Australian National University, Canberra.en_US
dc.description.conferencenameEpworth HealthCare Research Month 2023en_US
dc.description.conferencelocationEpworth Research Institute, Victoria, Australiaen_US
Appears in Collections:Research Month

Files in This Item:
File Description SizeFormat  
Epworth Research month poster Lynch PIPAC.pdf841.59 kBAdobe PDFThumbnail

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.